Another potent drug-target protein is RET, controlling five oncoproteins (MAPK3, PLK1, OPTN, PTTG1, CDH1) in the ovarian cancer network, Fig. 4 and Table 4. This evidence concerns the gene PLK1 and ovarian carcinoma.